CaseMark Managing Health Data Exchange
Structures health information exchange using HL7 FHIR R4, C-CDA, and legacy HL7 v2 messaging to meet Cures Act interoperability mandates. This skill covers technical implementation, participant onboarding, TEFCA alignment, and operational monitoring of data exchange channels.
Why This Skill Exists
The 21st Century Cures Act and ONC's information blocking rules (45 CFR Part 171) require that health IT systems exchange electronic health information without unreasonable barriers. Organizations face regulatory penalties, reputational risk, and clinical quality gaps when data exchange fails. Simultaneously, the transition from point-to-point HL7 v2 interfaces to RESTful FHIR APIs and TEFCA-based nationwide exchange introduces architectural complexity that requires disciplined management.
The transition from legacy point-to-point HL7 v2 interfaces to modern FHIR-based APIs and TEFCA-mediated nationwide exchange represents the most significant architectural shift in health IT interoperability since the adoption of HL7 v2 in the 1990s. Organizations must manage this transition while maintaining operational continuity for existing interfaces and meeting evolving regulatory timelines.
Checkpoint A --- Intake & Scoping
Answer every question before proceeding. Mark unknowns with [VERIFY].
- Exchange use case --- What clinical or operational need drives this exchange? (Care transitions, referral management, public health reporting, payer data exchange, patient access)
- Participants --- Which organizations or systems are involved? List sending and receiving parties with their EHR/HIS platform and version
- Data scope --- What USCDI data classes and elements are required? Reference USCDI v4 categories explicitly
- Exchange pattern --- Push (sender-initiated), pull (query-response), or subscription (event-driven)? Batch or real-time?
- Standards in use --- HL7 v2 (specify message types: ADT, ORM, ORU, MDM), C-CDA (specify document types: CCD, Referral Note, Discharge Summary), FHIR R4 (specify resources and operations)
- TEFCA participation --- Is either party a TEFCA Qualified Health Information Network (QHIN) participant? Which TEFCA exchange purpose applies?
- Regulatory obligations --- Promoting Interoperability, information blocking compliance, state consent management requirements
Required Documents
- Interface specification or implementation guide (HL7 v2 conformance profile, C-CDA template constraints, FHIR IG)
- Network connectivity requirements (VPN, TLS mutual auth, DIRECT messaging)
- USCDI v4 data element checklist for the exchange scope
- Data use agreement (DUA) or business associate agreement (BAA) between parties
- Patient consent policy documentation (especially for behavioral health, substance use, HIV data under 42 CFR Part 2)
Step 1 --- Assess Current Exchange Architecture
Map the existing data exchange landscape:
Interface inventory --- Document every active interface: source system, destination system, message type, transport protocol, message volume (daily average), and error rate
Standards gap analysis --- Identify where legacy HL7 v2 interfaces could be migrated to FHIR R4. Prioritize by: (a) regulatory requirement (patient access APIs must be FHIR), (b) maintenance burden, (c) data quality issues
Connectivity topology --- Map hub-and-spoke vs. point-to-point vs. HIE-mediated connections. Identify single points of failure
FHIR endpoint catalog --- Inventory existing FHIR servers, their capability statements, supported resources, and authentication methods
TEFCA readiness assessment --- Evaluate organizational readiness for TEFCA participation: identity proofing infrastructure, master patient index capabilities, FHIR endpoint maturity, consent management for sensitive data categories, and operational capacity to respond to TEFCA queries from external QHINs
Step 2 --- Design the Exchange Specification
For each exchange channel, produce a technical specification:
FHIR implementation --- Define the FHIR resources required (Patient, Condition, MedicationRequest, Observation, DocumentReference, Encounter), required vs. optional elements, search parameters, and _include/_revinclude chains
C-CDA document exchange --- Specify template conformance (C-CDA R2.1 with USCDI companion guide extensions), required sections (Allergies, Medications, Problems, Results, Procedures), and null-flavor handling rules
HL7 v2 messaging --- Define segment-level specifications: MSH (sending/receiving facility, message type, version), PID (patient identifiers, MRN crosswalk), OBX (result segments with LOINC codes and units)
Patient matching --- Specify the matching algorithm: deterministic (MRN, SSN last-4 + DOB + name) or probabilistic (weighted scoring). Define match threshold, possible-match threshold, and no-match handling
Consent enforcement --- For sensitive data categories (42 CFR Part 2 substance use, state behavioral health laws), define the consent-checking mechanism: pre-exchange consent query, consent directive in the payload, or consent management service
Bulk FHIR export --- For large-scale data exchange (payer access, research, public health), implement FHIR Bulk Data Access (Flat FHIR) per the SMART Backend Services specification. Define access controls, rate limiting, and audit logging for bulk export operations
Step 3 --- Implement Security and Trust
Data exchange requires layered security:
- Transport security --- TLS 1.2 minimum for all connections. Mutual TLS (mTLS) for FHIR server-to-server communication. DIRECT messaging for secure email-based exchange
- Authentication and authorization --- SMART on FHIR OAuth 2.0 for patient-facing and EHR-launch apps. SMART Backend Services (client_credentials grant with signed JWT assertions) for system-to-system exchange
- Identity proofing --- Validate participant organization identity through TEFCA QHIN credentialing, DirectTrust accreditation, or manual verification
- Audit logging --- Log every exchange event: timestamp, sender, recipient, patient identifier, data elements exchanged, success/failure, and user identity. Retain logs per HIPAA requirements (minimum 6 years)
- Breach notification readiness --- Define the escalation path if exchanged PHI is exposed. Integrate with the organization's HIPAA breach notification process
Step 4 --- Onboard Exchange Partners
Structured partner onboarding prevents production failures:
- Legal/compliance review --- Execute DUA/BAA. Confirm both parties' information blocking compliance posture
- Technical connectivity --- Establish network connectivity (VPN tunnels, firewall rules, certificate exchange)
- Testing progression --- Connectivity test (can systems reach each other), message validation test (do messages parse correctly), clinical scenario test (do realistic clinical scenarios produce correct data), volume test (peak-load simulation)
- Go-live criteria --- Define message acceptance rate threshold (> 99.5%), maximum acceptable latency, and error handling procedures before activating production exchange
- Monitoring handoff --- Establish ongoing monitoring responsibilities and escalation contacts for both parties
- Consent management architecture --- For organizations exchanging sensitive data (42 CFR Part 2 substance use, state behavioral health, HIV, genetic data), implement a consent management service that: stores granular patient consent directives, evaluates consent at query time, enforces consent restrictions in real-time, and logs all consent-based access decisions for audit
Step 5 --- Monitor and Optimize
Ongoing operational management:
Dashboard metrics --- Message volume (hourly, daily, weekly trends), error rate by error type (parse failure, patient match failure, timeout, authentication failure), latency (p50, p95, p99), and queue depth
Error triage protocol --- Categorize errors: (a) transient (retry automatically), (b) data quality (requires source system fix), (c) configuration (requires interface team action), (d) systemic (requires architecture change)
FHIR API performance --- Monitor FHIR server response times, concurrent connection counts, and resource utilization. FHIR queries returning > 200 resources should use pagination
Reconciliation --- Weekly automated reconciliation of sent vs. received message counts between partners. Investigate discrepancies > 0.1%
Standards version management --- Track upcoming HL7 ballot cycles, FHIR version updates (R4 to R4B to R5), and USCDI version changes that affect exchange content requirements
Migration planning (v2 to FHIR) --- For legacy HL7 v2 interfaces targeted for FHIR migration, develop a phased migration plan: inventory current v2 interfaces by message type and criticality, map v2 segments to equivalent FHIR resources, implement dual-stack (v2 and FHIR in parallel) during transition, validate FHIR output against v2 baseline, and decommission v2 only after successful FHIR validation
Checkpoint B --- Exchange Operations Review
Before declaring the exchange channel production-ready:
Technical specification is complete and approved by both parties
All testing stages are passed with documented evidence
Patient matching accuracy meets organizational threshold
Consent management is validated for sensitive data categories
Security controls (TLS, OAuth, audit logging) are verified
Monitoring dashboards are operational with alerting configured
Error handling and escalation procedures are documented
DUA/BAA is executed and on file
TEFCA readiness assessment is completed with gap remediation plan
Consent management is validated for all sensitive data categories in the exchange
Migration plan from v2 to FHIR is documented for legacy interfaces
Quality Audit
USCDI v4 data elements required for the use case are confirmed in the exchange payload
FHIR resources validate against the applicable implementation guide (US Core, Da Vinci, CARIN)
C-CDA documents pass validation against C-CDA R2.1 schema and Schematron rules
Information blocking exceptions (45 CFR Part 171) are documented if any data is excluded from exchange
Patient matching false-positive and false-negative rates are measured and within tolerance
Transport security meets HIPAA technical safeguard requirements
Audit logs capture all required exchange metadata
Exchange volume meets or exceeds projected clinical workflow demand
Partner onboarding documentation is archived for compliance audit
FHIR Bulk Data Access is configured with appropriate access controls and rate limiting
Consent management service enforces patient consent directives for sensitive data categories
v2-to-FHIR migration plan includes dual-stack validation and rollback capability
TEFCA Common Agreement technical requirements are mapped against organizational capabilities
Guidelines
Treat information blocking compliance as a default posture: exchange all EHI unless a specific Cures Act exception (privacy, security, infeasibility, health IT performance, content/manner, fees, licensing) applies and is documented
Use US Core FHIR profiles as the baseline for all FHIR exchange. Do not invent custom profiles when US Core covers the use case
For C-CDA, validate every document against the ONC reference validator before sending. Invalid C-CDAs that fail at the receiving system create clinical gaps
Never rely solely on MRN for patient matching across organizations. MRNs are facility-specific and collide across systems
Monitor HL7 v2 interface engines (Rhapsody, Mirth Connect, Cloverleaf) for message queue buildup. A growing queue is an early warning of downstream system issues
When onboarding TEFCA exchange, follow the Common Agreement technical requirements for QHIN-to-QHIN query and message delivery
Design for failure: every exchange channel needs a documented degradation mode (store-and-forward, manual fax fallback) for when electronic exchange is unavailable
Re-assess exchange architecture annually against evolving USCDI versions and ONC rulemaking
FHIR is the future standard but HL7 v2 is the present reality. Plan for 5-10 years of coexistence. Migration must be incremental and risk-managed, not a big-bang replacement
Consent management for sensitive data is the hardest interoperability problem in healthcare. Technical solutions exist but organizational policy, patient communication, and legal compliance must be aligned before implementation